为肝细胞癌武装 GPC3 CAR-T 细胞：多少才足够，下一步是什么？
Armouring GPC3 CAR T cells for hepatocellular carcinoma: how much is enough and what comes next?
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
酪氨酸激酶抑制剂作为肝细胞癌过继性 T 细胞疗法的潜在增敏剂
英文原题：Tyrosine kinase inhibitors as potential sensitizers of adoptive T cell therapy for hepatocellular carcinoma.
查看英文原题
Tyrosine kinase inhibitors as potential sensitizers of adoptive T cell therapy for hepatocellular carcinoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
肝细胞癌（HCC）是全球范围内高发的恶性肿瘤，缺乏有效的治疗选择。靶向药物是肝细胞癌全身治疗的首选推荐。免疫治疗是包括HCC在内的恶性肿瘤全身治疗的突破。然而，单独使用靶向治疗或免疫治疗均疗效有限，对部分HCC患者的生存获益有限。研究已证实，酪氨酸激酶抑制剂（TKIs）对肿瘤微环境和免疫应答具有调节作用，是免疫治疗的潜在增敏剂。在此，TKIs与免疫治疗的联合治疗已被探索并证明可提高治疗有效性。作为一种有效的免疫治疗，实体瘤中的过继性T细胞治疗需要提高肿瘤浸润和杀伤活性，这或许可以通过与TKIs联合来实现。
展开英文摘要原文
Hepatocellular carcinoma (HCC) is a high-incidence malignant tumor worldwide and lacks effective treatment options. Targeted drugs are the preferred recommendations for the systemic treatment of hepatocellular carcinoma. Immunotherapy is a breakthrough in the systemic treatment of malignant tumors, including HCC.
However, either targeted therapy or immunotherapy alone is inefficient and has limited survival benefits on part of HCC patients. Investigations have proved that tyrosine kinase inhibitors (TKIs) have regulatory effects on the tumor microenvironment and immune response, which are potential sensitizers for immunotherapy.
Herein, a combination therapy using TKIs and immunotherapy has been explored and demonstrated to improve the effectiveness of treatment. As an effective immunotherapy, adoptive T cell therapy in solid tumors is required to improve tumor infiltration and killing activity which can be possibly achieved by combination with TKIs.
论文信息
- 作者
- Liang L、Wang X、Huang S、Chen Y、Zhang P、Li L、Cui Y
- 第一作者单位
- Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China.China
- 通讯作者单位
- Department of Oncology, Shenzhen Qianhai Shekou Free Trade Zone Hospital, Shenzhen, Guangdong, China.China
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- Frontiers in immunology2023
- 原文标识
- PubMed 36936932 · DOI 10.3389/fimmu.2023.1046771
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →